News and Announcements
News for MTM Film Holdings’ Investors
- Published March 02, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
All Investors in MTM Film Holdings Pty Ltd will have their names featured in the credits of Molly the Magnificent, and provided with two tickets to the Australian Premiere.
About MTM FIlm Holdings Pty Ltd
100% Tax deduction – Priority Gross Revenue Participation – Legacy Australian Film Experience.
MTM Film Holdings Pty Ltd is a Special Purpose Vehicle set up by Wallace Media Group Limited for the production of it’s Australian feature film – Molly The Magnificent.
Written in the style of Little Miss Sunshine and Driving Miss Daisy by James Wallace and Glenn Fraser, Molly The Magnificent is a feel-good Australian story reminiscent of The Castle.
The film embraces three generations of unknowingly exceptional Australians simultaneously fighting their own battles yet dependent on each other to survive. It’s a love story rarely told yet familiar to us all.
The film has a $1.5mil budget and has $750k available for private investors in exchange for 50% of the copyright and gross revenue rights.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
